Stay updated with breaking news from Global Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-Total Revenues of $2.0 Billion in 2022, Including 23 Percent Annual Increase in Total Net Product Sales to $1.7 Billion--TUKYSA Granted FDA Accelerated Approval for Previously Treated RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer--ADCETRIS Received Pediatric Indication with FDA Approval for Children wit...
Pierre Fabre to Lead Launch and Commercialization Activities for EBVALLO In Europe Following Transfer of European Commission Marketing Authorization from Atara Biotherapeutics EBVALLO is the
Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – January 9, 2023 Idorsia Ltd today announced that Jean-Paul Clozel, Chief Executive Officer of Idorsia, will present at the... | January 9, 2023
For Idorsia, 2022 has been a roller coaster ride, mostly downhill. What transpired in 2022 for IDRSF and why do I still rate it a Hold? Click here to find out.